Nicardipine Aguettant

Nicardipine Aguettant Use In Pregnancy & Lactation



Laboratoire Aguettant


HK Medical Supplies
Health Express
Full Prescribing Info
Use In Pregnancy & Lactation
Pregnancy: Animal studies have shown no teratogenic effects. In the absence of teratogenic effects in animals, no malformative effect is expected in humans. In fact, until now, substances responsible for malformations in humans have always been demonstrated to be teratogenic in animals during studies carried out well in two species. Nicardipine should only be used if the benefit outweighs the risk because a reduction of birth weight in newborns has been reported when used in combination with calcium channel blockers.
Limited pharmacokinetic data have shown that nicardipine IV does not accumulate and has a low placental transfer.
In clinical practice, the use of nicardipine during the first two trimesters in a limited number of pregnancies has not revealed any malformative or particular foetotoxic effect to date.
The use of nicardipine for severe pre-eclampsia during the third trimester of pregnancy could potentially produce an undesirable tocolytic effect which could potentially interfere with the spontaneous induction of labour.
Acute pulmonary oedema has been observed when nicardipine has been used as tocolytic during pregnancy (see Precautions and Adverse Reactions), especially in cases of multiple pregnancy (twins or more), with the intravenous route and/or concomitant use of beta-2-agonists. Nicardipine should not be used in multiple pregnancies or in pregnant women with compromised cardio-vascular condition, except if there is no other acceptable alternative.
Breast-feeding: Nicardipine should not be used during breast-feeding (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Fertility: Not applicable.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in